If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
Holding of a webinar today, Monday March 21 at 1:30 p.m. by the management of GeNeuro, to present these results and the latest advances of the Company
– Achievement of the primary endpoint of the ProTEct-MS study: the results confirm the excellent safety and tolerability profile of higher doses of temelimab administered at the same time as a highly effective anti-inflammatory
– Efficacy data, obtained in patients already treated effectively against inflammation, showed that temelimab has a favorable impact on key MRI parameters measuring neurodegeneration
– The effect sizes observed in this new patient population were consistent with those shown in previous CHANGE-MS and ANGEL-MS studies